The FDA's sentinel initiative--A comprehensive approach to medical product surveillance

R Ball; M Robb; S A Anderson; G Dal Pan

doi:10.1002/cpt.320

The FDA's sentinel initiative--A comprehensive approach to medical product surveillance

Clin Pharmacol Ther. 2016 Mar;99(3):265-8. doi: 10.1002/cpt.320. Epub 2016 Jan 12.

Authors

R Ball¹, M Robb¹, S A Anderson², G Dal Pan¹

Affiliations

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
² Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

PMID: 26667601
DOI: 10.1002/cpt.320

Abstract

In May 2008, the Department of Health and Human Services announced the launch of the Sentinel Initiative by the US Food and Drug Administration (FDA) to create the Sentinel System, a national electronic system for medical product safety surveillance. This system complements existing FDA surveillance capabilities that track adverse events reported after the use of FDA regulated products by allowing the FDA to proactively assess the safety of these products.

Published 2016. This article is a US Government work and is in the public domain in the USA.

MeSH terms

Adverse Drug Reaction Reporting Systems
Equipment and Supplies / adverse effects
Equipment and Supplies / standards
Humans
Pharmacovigilance
Product Surveillance, Postmarketing*
United States
United States Food and Drug Administration / legislation & jurisprudence*